Treatment results of bisphosphonate-related osteonecrosis of the jaws

Head and Neck

Volumn 30, Issue 9, 2008, Pages 1224-1230

  Wutzl, Arno ^a   Biedermann, Edwin ^a   Wanschitz, Felix ^a   Seemann, Rudolf ^a   Klug, Clemens ^a   Baumann, Arnulf ^a   Watzinger, Franz ^a   Schicho, Kurt ^a   Ewers, Rolf ^a   Millesi, Gabriele ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bisphosphonates; Jaws; Osteonecrosis; Prospective treatment outcomes; Surgery

Indexed keywords

ALENDRONIC ACID; AMOXICILLIN; BISPHOSPHONIC ACID DERIVATIVE; CHLORHEXIDINE; CLAVULANIC ACID; CLINDAMYCIN; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BIPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW; BONE NECROSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MAXILLA RESECTION; MUCOSA; PAIN ASSESSMENT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTHESIS; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COHORT STUDIES; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; OSTEOPOROSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 51949083037     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20864     Document Type: Article

References (21)

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic [Letter]. J Oral Maxillofac Surg 2003;61:1115-1118.
2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff S. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
3. Migliorati CA. Bisphosphanates and oral cavity cancer avascular bone necrosis (correspondence). J Clin Oncol 2003;21:4253-4254.
4. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;6:1104-1107.
5. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005;63:1567-1575.
6. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
7. Bagan JV, Jimenez Y, Murillo J, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases [Letter]. Oral Oncol 2006;42:327-329.
8. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761.
9. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaws and bisphosphonates [Letter]. N Engl J Med 2005; 353:99-102.
10. Wutzl A, Eisenmenger G, Hoffmann M, et al. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien Klin Wochenschr 2006;118:473-478.
11. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-689.
12. Hohnecker JA. Novartis "Dear Doctor" precautions added to label of Aredia and Zometa, Novartis; 2004 (open letter to Austrian dental practitioners).
13. Combidex briefing information. United States Food and Drug Administration Oncologic Drugs Advisory Committee. Available at http://www.fda.gov/ohms/ dockets/ac/05/briefing/2005-4095b1.htm (accessed July 2005).
14. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaws and bisphosphonates [Letter]. N Engl J Med 2005;353:99-102.
15. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-8587.
16. Advisory task force on bisphosphonate-related ostenonecrosis of the jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-376.
17. Groetz KA, Kreusch T. Zahnärztliche Betreuung von Patienten nach Bisphosphonat-Medikation. Dtsch Zahnärztl Z 2006;60:1-11.
18. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonȩcrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136:1658-1668.
19. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 2005;136:1675-1681.
20. Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws, Professional education material, Novartis, June 2004.
21. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-441.